Genitourinary Cancers

The combination of CB-839, a selective inhibitor of glutaminase, and everolimus seems to have disease activity in patients with advanced renal cell carcinoma.

Patients with metastatic renal cell carcinoma treated with sunitinib often experience treatment-related hypertension and require rigorous blood pressure control.

The use of radiotherapy was associated with an overall survival benefit in patients with prostate cancer and lymph node involvement who underwent radical prostatectomy and were also treated with androgen-deprivation therapy.

Metastatic renal cell carcinoma (mRCC) patients who use non-aspirin NSAIDs have poorer overall survival than aspirin users and NSAID non-users, according to a new pooled retrospective analysis.

A recent study published in European Urology suggests that patterns of treatment failure might help to predict what the next treatment should be for patients with metastatic renal cell carcinoma.

Medical researchers at Indiana University Bloomington are reporting that prostate cancer may be much more closely related to Ewing’s sarcoma than previously recognized.

With a number of therapies now available for treatment of renal cell carcinoma, research is now ongoing to determine the best possible sequencing and potential combinations of those therapies.

The use of proton pump inhibitors does not appear to impact the efficacy of oral VEGF tyrosine kinase inhibitors in metastatic renal cell carcinoma, according to a new study.

The use of immune checkpoint inhibitors as adjuvant or neoadjuvant therapy in kidney cancer could offer important new treatment options. Questions remain, though, on the timing and sequence of therapy.

Specific tumor genotypes could represent distinct subtypes of clear cell renal cell carcinoma, according to a new analysis of the RECORD-3 trial. Genotyping could potentially help guide treatment decisions if the results can be validated.

A small study found that patients with metastatic renal cell carcinoma (mRCC) who discontinue nivolumab due to immune-related adverse events can continue to derive benefit even after cessation of therapy.

The combination of bevacizumab and an investigational nanoparticle-drug conjugate known as CRLX101 failed to improve outcomes in metastatic renal cell carcinoma compared with standard of care.

A phase III study of adjuvant girentuximab in patients with high-risk clear cell RCC showed that the drug provided no clinical benefit compared with placebo.

The immune checkpoint antibody pembrolizumab (Keytruda, Merck) improved survival in previously treated advanced urothelial cancer compared to chemotherapy, according to the manufacturer of the immunotherapy.

The combination of cabazitaxel and abiraterone was well tolerated and showed antitumor activity in previously treated patients with metastatic castration-resistant prostate cancer.

A new study showed that a 24-gene signature can predict outcomes following postoperative radiotherapy in patients with prostate adenocarcinoma who underwent radical prostatectomy.

Androgen deprivation therapy (ADT), a mainstay of treatment for men with prostate cancer, may raise the risk of dementia, according to a new study.

The addition of the IMA901 vaccine to sunitinib for the first-line treatment of metastatic renal cell carcinoma did not improve overall survival.

New immunotherapies that target PD-1 are now showing promise for first-line and second-line treatment of metastatic bladder cancer.

Pembrolizumab showed clinical activity against some cases of enzalutamide-refractory metastatic castration-resistant prostate cancer.

Treatment with cabozantinib resulted in significantly improved PFS and overall response vs sunitinib for patients with metastatic renal cell carcinoma.

Patients with renal cell carcinoma at high risk for recurrence had prolonged disease-free survival when treated with sunitinib compared with placebo.

Patients with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases (liver and lung) fare better with the androgen receptor inhibitor enzalutamide than placebo, according to a new analysis from the phase III AFFIRM trial.

Combining two cancer immunotherapies to target both the interleukin 10 (IL-10) and programmed cell death protein 1 (PD-1) receptors has yielded promising early results for some patients with renal cell carcinoma and non-small cell lung cancer.

The FDA announced a modification to the recommended dosage regimen for nivolumab (Opdivo) for renal cell carcinoma (RCC), metastatic melanoma, and non–small-cell lung cancer (NSCLC).

Men who have vasectomies do not have a higher risk of prostate cancer and are not more likely to die from the disease, according to a large, prospective study.

The gene known as β-Klotho (KLβ) appears to play an important role in tumor invasion and progression in patients with bladder cancer, and urine KLβ levels may act as a useful biomarker, according to a new study.

Investigators at the University of Colorado Cancer Center and Yale University are now reporting in the journal Cancer Cell on a new understanding of the cancer suppressing gene RhoDGI2 and how it may be involved in metastatic bladder cancer.

Patients with metastatic RCC and a BMI of 25 or greater had significantly longer overall survival compared with patients with a BMI of less than 25, according to the results of a recent study.

While survival at 10 years was nearly identical (close to 99%), a new study found that localized prostate cancer is more likely to metastasize in men receiving active surveillance compared with those who have surgery or radiation therapy.